Date October 6, 2016 Contact Information

Heather A. Curry, M.D

Medical Director,

University of Maryland Radiation Oncology Center at Union Hospital

Center at Union Hospital

152 Railroad Avenue

Elkton, MD 21921

Business Phone Number: 443-907-1650

Email: heathercurray@umm.edu

1995 M.D., Temple University School of Medicine

1996—2000 Residency, Radiation Oncology, Barnes-Jewish Hospital, Washington University in St. Louis

1994 USMLE Step 2 CK

1995 USMLE Step 3

2000 Diplomat, American Board of Radiology, Radiation Oncology

2010 Diplomat, Recertification, American Board of Radiology, Radiation Oncology

2012 Diplomat, American Board of Radiology, Hospice and Palliative Medicine

Active Delaware issued 2012

Active Maryland reissue 2016

Inactive Pennsylvania (training license)

Inactive Missouri (training license)
Employment History
Academic Appointments
2001—2002 Assistant Professor, Radiation Oncology Thomas Jefferson University

2016 – present Assistant Professor, Radiation Oncology University of Maryland School of Medicine

2002—2012 Physician, Radiation Oncology, Paoli Hospital, Paoli, PA

2012—present Director, Radiation Oncology, NantHealth, Philadelphia, PA

2013—present Consultant, Associate Medical Director, Compassionate Care Hospice, Wilmington, DE

2015—2016 Consultant, Radiation Oncology, Precision Radiation Oncology, Crozer Keystone Brinton Lakes, Glen Mills PA

2016 – present Medical Director, Radiation Oncology Center at Union Hospital

2011—present American Association of Hospice and Palliative Medicine

2013—present Society of Palliative Radiation Oncology
Honors and Awards
1991 Honors awarded in Philosophy, Bryn Mawr College

1992 St. George - American Cancer Society Summer Internship in Oncology

1998 Oxygen Society Young Investigator's Award

1999 Young Oncologist Essay Award, American Radium Society

2000 Resident Research Award in Radiation Oncology, American Association of Women Radiologists

2009, 2010, 2011 Named a Top Physician by Main Line Today Magazine

Additional board certification in the subspecialty of hospice and palliative medicine.

Clinical focus in management of breast cancer, central nervous system tumors, and palliative radiotherapy.

Research focus on practice patterns and cost implications in radiation oncology with regard to alignment with evidence based practices and professional society recommendations.

~200 new patient consults per year

Lead clinical and administrative role

80% FTE clinical; 20% FTE administrative

Management of 5—15 general inpatient (GIP) hospice/palliative care patients

Coverage of ~50 home hospice/palliative care patients

Average 1 weekend per month

Provide clinical cross-coverage 1 day per week of average 25 patients under active radiation treatment; perform 1—2 consults per week; participate in weekly chart rounds and departmental quality assurance initiatives

20% FTE
2016 – present University of Maryland Radiation Oncology Center at Union Hospital

Medical Director, Radiation Oncology Center

Clinical and administrative role

Development of Clinical Programs
2003 Implemented IMRT program at Paoli Hospital

2006 Developed Breast Brachytherapy Program at Paoli Hospital

2010 Implemented IGRT and Gating programs at Paoli Hospital
Administrative Service
Institutional Service
2001—2002 Radiation Oncology Residency Program Director, Thomas Jefferson University Hospital

2003—2012 Cancer Committee, Paoli Hospital

2003—2012 Institutional Review Board, Paoli Hospital

2003—2012 Radiation Safety Committee, Paoli Hospital

2007—2012 Medical Operations Committee, Paoli Hospital

2008—2010 Medical Executive Committee, Main Line Health System

2008—2012 Breast Program Steering Committee, Paoli Hospital

2009—2012 Physicians Advisory Group, Paoli Hospital

2009—2012 Bylaws Committee, Main Line Health System

Teaching Service
2001—2002 Attending Physician Outpatient radiation oncology service, 1 resident, 1 fellow, 8 hours per day


Publications
Peer-reviewed journal articles
1. Gius, D., Botero, A., Shah S., and Curry, H.A.: Intracellular oxidation/reduction status in the regulation of transcription factors NF-kB and AP-1. Toxicology Letters 106:93-106, 1999.

2. Curry, H.A., Clemens, R.A., Botero, A.C., Spitz, D.R., and Gius, D.: Heat Shock inhibits radiation-induced activation of NF-kB via inhibition of I-kB kinase. Possible role in radiation sensitization of tumor cells. JBC 274:23061-23067, 1999.

3. Zoberi, I., Bradbury, C.M., Curry, H.A., Bisht, K.S., Goswami, P.C., Roti Roti, J.L, and Gius, D.: Radiosensitizing and anti-proliferative effects of resveratrol in two human cervical tumor cell lines. Cancer Letters. 175(2):165-73, 2002. (performed supplemental and confirmatory experiments to validate main research projects)

4. Bisht KS, Bradbury CM, Zoberi I, Curry H.A, Kaushal A, Roti Roti JL, Gius D., Inhibition of cyclooxygenase-2 with NS-398 and the prevention of radiation-induced transformation, micronuclei formation and clonogenic cell death in C3H 10T1/2 cells. Int J Radiat Biol. 79(11):879-88, 2003. (provided data and figures to supplement major research directive)

5. Mattson D, Bradbury CM, Bisht KS, Curry HA, Spitz DR, Gius D. Heat shock and the activation of AP-1 and inhibition of NF-kappa B DNA-binding activity: possible role of intracellular redox status. Int J Hyperthermia. 20(2):224-33, 2004. (provided data and figures to supplement major research directive)

6. Morganroth PA, Dehoratius D, Curry H, Elenitsas R.: Postirradiation Morphea: A Case Report With a Review of the Literature and Summary of the Clinicopathologic Differential Diagnosis.. Am J Dermatopathol. 2013 Oct 4. [Epub ahead of print] (provided clinical information for case report; assisted in review and interpretation of pertinent literature related to phenomena of postirradiation morphea)

1. 
   Curry HA and Curran WJ. Chemoradiation strategies for patients with malignant gliomas. In: Chemoradiation in Cancer Therapy. Choy H, ed. Humana Press. 2003: 129—144.
   
2. 
   Curry HA. Quality and the Third-Party Payer. In: Quality and Safety in Radiation Oncology. Implementing Tools and Best Practices for Patients, Providers, and Payers. Dicker A., Williams T. and Ford E. eds. Demos Medical Publishing 2016: 297—308.
   

2. Curry, H.A., Clemens, R.A., Spitz, D.R., Botero, A., Lofrem, S., and Gius, D.: Heat shock inhibits radiation-induced activation of /dNA-binding and nuclear localization of NF-kB. Free Radical Biology & Medicine 25(S1):S108, 1998.

3. Curry, H.A., Botero, A., Clemens, R.A., Shah, S. and Gius, D.: Heat shock inhibits radiation-induced activation of NF-kB via inhibition of I-kB kinase (IKK). Possible novel mechanism of hyperthermic radiosensitation. Int J Radiat Biol. 45(3):183-184. 1999.

4. Curry, H.A. and Jagsi, R. Utilization of Hypofractionation in an Insured Population. Int J Radiat Biol. 87(2): S500–S501. 2013.

5. Curry, H.A., Palladino M.L., and Jagsi, R. Utilization of Hypofractionated Regimens for Treatment of Breast Cancer in an Insured Population Before and After Initiation of ASTRO’s “Choosing Wisely” Campaign. Int J Radiat Biol. 90(1): S62, 2014.

6. Curry, H.A., Palladino M.L., and Jagsi, R Utilization of Hypofractionated Regimens for the Treatment of Bone Metastases Before and After Initiation of ASTRO’s “Choosing Wisely” Campaign. Int J Radiat Biol. 90(1): S702. 2014.

7. Falchook, A., Hendrix, L.H., Curry, H.A., Chen, R.C., and Jagsi, R. Adoption of Intensity Modulated Radiation Therapy (IMRT) in Early-Stage Breast Cancer Patients Receiving Hypofractionated and Conventionally Fractionated Radiation in the United States. Int J Radiat Biol. 90(1): S228–S229. 2014. (proposed and assisted in development of key research question for study)

8. Curry, H.A., Forastiere, A.A., Flood, W.A., Whyler E., Hertan, L.M., Sharma, S. and Jones, JA. Utilization of single-fraction radiotherapy for the treatment of bone metastases before and after the “Choosing Wisely” campaign. J Clin Oncol. 32 (suppl 31; abstr 245), 2014.

9. Curry, H.A., Forastiere, A.A., Flood, W.A., Whyler E, Plastaras, J.P. and Vapiwala, N. Overutilization of IMRT/IGRT in treatment of rectal cancer: Cost implications of deviation from evidence-based practices. J Clin Oncol. 32 (suppl 30; abstr 34), 2014.

10. Jagsi,R., Falchook, A.D., Hendrix, L.H, Curry, H., and Chen, R.C. Adoption of Hypofractionated Radiation Therapy for Breast Cancer After Publication of Randomized Trials. Int J Radiat Biol. 90(5): 1001—1009, 2014. (proposed and assisted in development of key research question for study)

2. Curry, H.A., Clemens, R.A., Botero, A., Spitz, D.R., and Gius, D: Heat shock inhibits radiation-induced activation of NF-kB kinase. Possible role in radiation sensitization of tumor cells. American Radium Society. The Big Island, HI, 1999.

3. Curry, H.A., Botero, A., Clemens, R.A., Shah, S. and Gius, D: Heat shock inhibits radiation-induced activation of NF-kB via inhibition of I-kB kinase (IKK). Possible novel mechanism of hyperthermic radiosensitization. American Society of Therapeutic Radiation Oncology 41st Annual Meeting, San Antonio, TX, 1999.

4. Curry, H.A., Clemens, R.A., Botero, A.C., Bradbury, C.M., Spitz, D.R. and Gius, D: The role of selective cyclooxygenase inhibition in the cellular response of cervical cancer cells to ionizing radiation. The Radiological Society of North America 85th Annual Meeting. Chicago, IL, 1999.

5. 
   Curry, H.A. Enabling Payment for Quality Oncology Care. Society of Radiation Oncology Administrators 30th Annual Meeting, Atlanta, GA, 2013. (invited speaker and panelist)